- Cancer research
- Career spotlights
- Customer stories
- Gene editing
- Single cell analysis
- Stem cell research
- Tips and troubleshooting
- ICYMI: 2018 blog posts
- About our blog
The SMARTer approach to RNA-seq of FFPE tissues
FFPE samples: a double-edged sword
Tissue banks are a valuable source of material, but their utility in RNA sequencing experiments has been limited due to many of these samples being formalin-fixed and paraffin-embedded (FFPE). This preservation method has proven crucial to advancing genetic research: by allowing samples to be archived long-term without specialized storage equipment, researchers are able to retroactively examine large numbers of tissue samples for gene expression changes. However, this fixation process results in severe degradation of nucleic acids and renders FFPE samples a challenging source material for RNA-seq.
These difficulties spurred us to develop the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian (referred to below as "Pico v2"), which leverages our proprietary template-switching SMART technology to enable the use of as little as 250 pg of input RNA of any quality (see workflow below). Our Pico v2 kit was put to the test against several competitors' kits in a head-to-head comparison of RNA-seq of FFPE samples. Spoiler alert: we passed with flying colors!
At ABRF 2018, the Tighe group (University of Vermont) presented data where they used human thyroid tumor FFPE samples (n = 6) to generate RNA-seq data. The authors analyzed the performance of our kit (Pico v2) versus two competitors' kits (Diagenode CATS Total RNA-Seq Kit V2I and X Total RNA Library Prep Kit V1), directly comparing various sequencing quality metrics (Table 2) as well as transcript coverage (Figure 2 and 3).
All three kits exhibited per-sample variability in the number of total, rRNA, and filtered reads; however, in all six samples, our Pico v2 kit detected the most transcripts, with up to 763% more than the closest competitor (median of 143%) and superior expression profiling efficiency (Table 2). Furthermore, in five out of six cases, our kit demonstrated the highest uniquely mapped raw read count and percentage of uniquely mapped reads as well as the highest exonic rate. While our Pico v2 kit only had the lowest duplication rate in 2 out of 6 samples, we note that duplication rate is influenced by read depths and, as such, the differences in duplication rates are expected under the circumstances. Combined, these results indicate that our kit's performance was the least impacted by severe RNA degradation and low sample quality—a key metric, given the high degree of variability in FFPE samples.
The Pico v2 kit also demonstrated superior transcript coverage in both high- and low-expression transcripts (Figures 2 and 3, respectively). Our kit demonstrated more even coverage of both high- and low-expression transcripts (average of ~30X coverage), particularly compared to a competitor's kit that exhibited a marked bias towards the 3' end of transcripts.
Despite the difficulties of sequencing RNA in FFPE tissue samples caused by severe nucleic acid degradation, FFPE tissue samples will continue to be an essential sample source for genetic research. The SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian answers these challenges in a head-to-head competition by providing superior transcript detection and expression profiling efficiency, greater uniquely mapped reads, and the highest exonic rate of sequenced samples.
Back to Blog Front
Considering automating your single-cell analysis? Here are five features you should look for in a system.
Learn more about using unique molecular tags in your research for additional quality control of your PCR results.
A novel protocol that enables the detection of both SNVs and CNVs from 1-5 cells in a single, low-pass sequencing run that saves time and money.
Learn more about how the Allen Institute for Brain Science used our SMART-Seq v4 Ultra Low Input Kit for Sequencing to characterize specific cell types within human brain.
Learn how the many differences between popular scRNA-seq platforms impact your data. Here, we discuss sensitivity, read efficiency, and gene diversity (3' DE expression) data generated by the ABRF Genomics Research Group.
- Accurate detection of SNVs and CNVs from 5-cell inputs in a single, low-pass sequencing run
- Using the power of RNA-seq to characterize brain cell types
- When your his-tagged constructs don't bind
- Taking the SMARTer approach to RNA-seq of FFPE tissues
- Maximizing transduction efficiency in hematopoietic cells
- Efficient nonviral T-cell engineering: CRISPR takes a giant step towards the clinic
- Amplifying our understanding of breast cancer metastases
- How to choose the right tools for iPSC-derived disease model development
- Cardiac transcription heirarchies
- Bringing epigenomic profiling to the single-cell biology stage
- Top 5 considerations when automating single-cell sequencing
- What's inside automated single-cell RNA-seq platforms?
- Women in science at TBUSA
- Career spotlight: technical writer
- Career spotlight: field applications scientist
- Career spotlight: technical support scientist
- Career spotlight: associate director of R&D
- 5 tips to make your single-cell RNA-seq experiments a success
- Accelerating chromatin mapping with single-cell ATAC-seq
- Cancer immunotherapy
- Customer spotlight: profiling transcription factors with CUT&RUN sequencing
- Web and mobile apps
- Successful knockout experiments
- Using UMTs in NGS experiments
- One-step vs. two-step RT-qPCR
- Avoiding DNA contamination in PCR
- Choosing a CMO partner for stem cell therapy manufacturing
- 20 years of human stem cell research
- Better biobanking with high-throughput qPCR
- Accurate detection of SNVs and CNVs in a single, low-pass sequencing run
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2019 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.